Lyu Xuechan, Du Jiang, Zhan Guilai, Wu Yujie, Su Hang, Zhu Youwei, Jarskog Fredrik, Zhao Min, Fan Xiaoduo
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Xuhui District Mental Health Center, Shanghai, China.
Front Pharmacol. 2018 Mar 5;9:181. doi: 10.3389/fphar.2018.00181. eCollection 2018.
The rates of obesity and cigarette smoking are much higher in patients with schizophrenia compared to the general population. This study was to examine whether naltrexone and bupropion combination treatment can help weight loss and smoking cessation in patients with schizophrenia. Obese male schizophrenia patients with current cigarette smoking were randomized to receive adjunctive naltrexone (25 mg/day) and bupropion (300 mg/day) combination or placebo for 24 weeks. Twenty-two patients were enrolled in the study, and 21 patients completed the study (11 in the treatment group, and 10 in the placebo group). Body weight, body mass index (BMI), fasting lipids, smoking urge, expired carbon monoxide (CO) level and cigarettes smoked per week were measured at baseline and week 24. There was no significant difference between two groups in changes in weight, BMI, fasting lipids, or cigarette smoking measures ('s > 0.05) Naltrexone and bupropion combination treatment didn't show weight loss or smoking cessation effect in patients with schizophrenia in this pilot study.Implications for future studies were discussed. ClinicalTrials.gov identifier: NCT02736474.
与普通人群相比，精神分裂症患者的肥胖率和吸烟率要高得多。本研究旨在探讨纳曲酮和安非他酮联合治疗是否有助于精神分裂症患者减肥和戒烟。将目前吸烟的肥胖男性精神分裂症患者随机分为两组，分别接受辅助性纳曲酮（25毫克/天）和安非他酮（300毫克/天）联合治疗或安慰剂治疗，为期24周。该研究共纳入22例患者，21例患者完成了研究（治疗组11例，安慰剂组10例）。在基线和第24周时测量体重、体重指数（BMI）、空腹血脂、吸烟欲望、呼出一氧化碳（CO）水平和每周吸烟量。两组在体重、BMI、空腹血脂或吸烟指标的变化方面无显著差异（P>0.05）。在这项初步研究中，纳曲酮和安非他酮联合治疗对精神分裂症患者未显示出减肥或戒烟效果。文中讨论了对未来研究的启示。ClinicalTrials.gov标识符：NCT02736474。
